Critical Contrast: Teladoc Health (NYSE:TDOC) vs. Todos Med (OTCMKTS:TOMDF)

Teladoc Health (NYSE:TDOC) and Todos Med (OTCMKTS:TOMDF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.

Earnings and Valuation

This table compares Teladoc Health and Todos Med”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teladoc Health	$2.51 billion	0.53	-$200.32 million	($0.97)	-7.55
Todos Med	N/A	N/A	N/A	N/A	N/A

Todos Med has lower revenue, but higher earnings than Teladoc Health.

Risk and Volatility

Teladoc Health has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500. Comparatively, Todos Med has a beta of 0.05, meaning that its share price is 95% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Teladoc Health and Todos Med, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teladoc Health	1	11	5	0	2.24
Todos Med	0	0	0	0	0.00

Teladoc Health presently has a consensus price target of $7.43, indicating a potential upside of 1.48%. Given Teladoc Health’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Teladoc Health is more favorable than Todos Med.

Profitability

This table compares Teladoc Health and Todos Med’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Teladoc Health	-6.81%	-11.45%	-5.54%
Todos Med	N/A	N/A	N/A

Insider and Institutional Ownership

76.8% of Teladoc Health shares are owned by institutional investors. 0.7% of Teladoc Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Teladoc Health beats Todos Med on 7 of the 10 factors compared between the two stocks.

About Teladoc Health

Teladoc Health, Inc. provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment operates a mental health platform that provides online counseling and therapy services through website, mobile applications, phones, and text-based interactions by its licensed clinicians. The company offers its products and services under the Teladoc, Livongo, and BetterHelp brands. It serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was incorporated in 2002 and is headquartered in Purchase, New York.

About Todos Med

Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.